new path molecular research ltdEstimated Valuation
£612.7k
Pomanda estimates the enterprise value of NEW PATH MOLECULAR RESEARCH LTD at £612.7k based on a Turnover of £717k and 0.85x industry multiple (adjusted for size and gross margin).
new path molecular research ltdEstimated Valuation
£894.6k
Pomanda estimates the enterprise value of NEW PATH MOLECULAR RESEARCH LTD at £894.6k based on an EBITDA of £224.1k and a 3.99x industry multiple (adjusted for size and gross margin).
new path molecular research ltdEstimated Valuation
£490.4k
Pomanda estimates the enterprise value of NEW PATH MOLECULAR RESEARCH LTD at £490.4k based on Net Assets of £280.9k and 1.75x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
New Path Molecular Research LtdOverview
New Path Molecular Research Ltd is a live company located in cambridge, CB22 3AT with a Companies House number of 09412383. It operates in the other research and experimental development on natural sciences and engineering sector, SIC Code 72190. Founded in January 2015, it's largest shareholder is
steven ley
with a 26.6% stake. New Path Molecular Research Ltd is a established,
small sized company, Pomanda has estimated its turnover at
£717k with
declining
growth in recent years.
Pomanda's financial health check has awarded New Path Molecular Research Ltd a 3.5 rating. We use a traffic light system to show it exceeds the industry average on 3 measures and has 5 areas for improvement. Company Health Check FAQs
Health Rating3.5out of 5
3 Strong
2 Regular
5 Weak
Size
annual sales of £717k, make it smaller than the average company (£4.3m)
£717k - New Path Molecular Research Ltd
£4.3m - Industry AVG
Growth
3 year (CAGR) sales growth of -5%, show it is growing at a slower rate (7.4%)
-5% - New Path Molecular Research Ltd
7.4% - Industry AVG
Production
with a gross margin of 28.2%, this company has a higher cost of product (49.5%)
28.2% - New Path Molecular Research Ltd
49.5% - Industry AVG
Profitability
an operating margin of 31.3% make it more profitable than the average company (2.6%)
31.3% - New Path Molecular Research Ltd
2.6% - Industry AVG
Employees
with 5 employees, this is below the industry average (43)
5 - New Path Molecular Research Ltd
43 - Industry AVG
Pay Structure
on an average salary of £63.6k, the company has an equivalent pay structure (£63.6k)
£63.6k - New Path Molecular Research Ltd
£63.6k - Industry AVG
Efficiency
resulting in sales per employee of £143.4k, this is more efficient (£123.6k)
£143.4k - New Path Molecular Research Ltd
£123.6k - Industry AVG
Debtor Days
it gets paid by customers after 189 days, this is later than average (54 days)
189 days - New Path Molecular Research Ltd
54 days - Industry AVG
Creditor Days
its suppliers are paid after 97 days, this is slower than average (38 days)
97 days - New Path Molecular Research Ltd
38 days - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - New Path Molecular Research Ltd
- - Industry AVG
Cash Balance
There is insufficient data available for this Key Performance Indicator!
- - New Path Molecular Research Ltd
- - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 37.5%, this is a similar level of debt than the average (41.4%)
37.5% - New Path Molecular Research Ltd
41.4% - Industry AVG
NEW PATH MOLECULAR RESEARCH LTD financials
EXPORT
New Path Molecular Research Ltd's latest turnover from May 2024 is estimated at £717 thousand and the company has net assets of £280.9 thousand. According to their latest financial statements, New Path Molecular Research Ltd has 5 employees and maintains cash reserves of 0 as reported in the balance sheet.
Data source:Companies House, Pomanda Estimates
May 2024
May 2023
May 2022
May 2021
May 2020
May 2019
May 2018
May 2017
May 2016
Turnover
716,984
411,448
655,815
846,368
650,224
752,005
581,817
415,371
238,669
Other Income Or Grants
Cost Of Sales
514,702
301,628
501,866
620,145
472,234
526,027
423,010
310,091
174,985
Gross Profit
202,282
109,820
153,950
226,223
177,990
225,978
158,807
105,280
63,684
Admin Expenses
-21,866
272,807
267,472
28,855
220,402
216,687
70,266
-101,443
32,463
Operating Profit
224,148
-162,987
-113,522
197,368
-42,412
9,291
88,541
206,723
31,221
Interest Payable
Interest Receivable
62
124
Pre-Tax Profit
224,148
-162,987
-113,522
197,368
-42,412
9,291
88,541
206,785
31,345
Tax
-56,037
-37,500
-1,765
-16,823
-39,289
-6,269
Profit After Tax
168,111
-162,987
-113,522
159,868
-42,412
7,526
71,718
167,496
25,076
Dividends Paid
Retained Profit
168,111
-162,987
-113,522
159,868
-42,412
7,526
71,718
167,496
25,076
Employee Costs
317,950
371,275
296,658
351,635
349,552
559,275
447,970
157,561
101,652
Number Of Employees
5
6
5
6
6
10
8
3
2
EBITDA*
224,148
-162,987
-113,522
197,368
-42,412
9,291
88,541
206,723
31,359
* Earnings Before Interest, Tax, Depreciation and Amortisation
May 2024
May 2023
May 2022
May 2021
May 2020
May 2019
May 2018
May 2017
May 2016
Tangible Assets
7,198
1,133
3,947
11,585
26,298
47,207
64,557
57,356
2,222
Intangible Assets
Investments & Other
Debtors (Due After 1 year)
Total Fixed Assets
7,198
1,133
3,947
11,585
26,298
47,207
64,557
57,356
2,222
Stock & work in progress
Trade Debtors
373,006
147,917
319,568
428,266
305,441
283,072
227,482
141,935
62,912
Group Debtors
Misc Debtors
69,158
55,259
55,993
48,246
Cash
49,788
misc current assets
49,641
15,484
total current assets
442,164
203,176
375,561
476,512
305,441
283,072
277,123
157,419
112,700
total assets
449,362
204,309
379,508
488,097
331,739
330,279
341,680
214,775
114,922
Bank overdraft
Bank loan
Trade Creditors
136,941
56,983
63,920
53,843
52,335
58,463
77,390
22,203
89,803
Group/Directors Accounts
other short term finances
hp & lease commitments
other current liabilities
total current liabilities
136,941
56,983
63,920
53,843
52,335
58,463
77,390
22,203
89,803
loans
hp & lease commitments
Accruals and Deferred Income
other liabilities
31,547
34,563
39,838
44,982
50,000
provisions
total long term liabilities
31,547
34,563
39,838
44,982
50,000
total liabilities
168,488
91,546
103,758
98,825
102,335
58,463
77,390
22,203
89,803
net assets
280,874
112,763
275,750
389,272
229,404
271,816
264,290
192,572
25,119
total shareholders funds
280,874
112,763
275,750
389,272
229,404
271,816
264,290
192,572
25,119
May 2024
May 2023
May 2022
May 2021
May 2020
May 2019
May 2018
May 2017
May 2016
Operating Activities
Operating Profit
224,148
-162,987
-113,522
197,368
-42,412
9,291
88,541
206,723
31,221
Depreciation
138
Amortisation
Tax
-56,037
-37,500
-1,765
-16,823
-39,289
-6,269
Stock
Debtors
238,988
-172,385
-100,951
171,071
22,369
55,590
85,547
79,023
62,912
Creditors
79,958
-6,937
10,077
1,508
-6,128
-18,927
55,187
-67,600
89,803
Accruals and Deferred Income
Deferred Taxes & Provisions
Cash flow from operations
9,081
2,461
-2,494
-9,695
-70,909
-66,991
41,358
20,811
51,981
Investing Activities
capital expenditure
-6,065
2,814
7,638
14,713
20,909
17,350
-7,201
-55,134
-2,360
Change in Investments
cash flow from investments
-6,065
2,814
7,638
14,713
20,909
17,350
-7,201
-55,134
-2,360
Financing Activities
Bank loans
Group/Directors Accounts
Other Short Term Loans
Long term loans
Hire Purchase and Lease Commitments
other long term liabilities
-3,016
-5,275
-5,144
-5,018
50,000
share issue
-43
43
interest
62
124
cash flow from financing
-3,016
-5,275
-5,144
-5,018
50,000
19
167
cash and cash equivalents
cash
-49,788
49,788
overdraft
change in cash
-49,788
49,788
new path molecular research ltd Credit Report and Business Information
Very Low Risk70 - 100
Low Risk50 - 70
Moderate Risk30 - 50
High Risk20 - 30
Very High Risk0 - 20
Get a comprehensive credit check for new path molecular research ltd. Get real-time insights into new path molecular research ltd's credit score, group structure and payment trends.
New Path Molecular Research Ltd Competitor Analysis
Perform a competitor analysis for new path molecular research ltd by selecting its closest rivals, whether from the PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES sector, other small companies, companies in CB22 area or any other competitors across 12 key performance metrics.
new path molecular research ltd Ownership
NEW PATH MOLECULAR RESEARCH LTD group structure
New Path Molecular Research Ltd has no subsidiary companies.
Ultimate parent company
NEW PATH MOLECULAR RESEARCH LTD
09412383
NEW PATH MOLECULAR RESEARCH LTD Shareholders
The largest shareholders in New Path Molecular Research Ltd include Steven Ley and Kcp Nominees Ltd.
steven ley
26.65%
kcp nominees ltd
15.15%
elizabeth farrant
12.77%
nikzad nikbin-roudsari
12.77%
reyker nominees ltd
9.14%
duncan mcinnes
3.06%
andrew maccormack
2.5%
jan paul van driel
1.81%
kcp nominees (dbc-bbi account) ltd
1.51%
david lewis
1.39%
new path molecular research ltd directors
New Path Molecular Research Ltd currently has 5 directors.
The longest serving directors include
Ms Elizabeth Farrant (Jan 2015) and
Mr Andrew MacCormack (May 2015).
72190 - Other research and experimental development on natural sciences and engineering
incorporation date
January 2015
age
10
incorporated
UK
ultimate parent company
None
accounts
Micro-Entity Accounts
last accounts submitted
May 2024
previous names
N/A
accountant
BAKER WATKIN ACCOUNTING LTD
auditor
-
address
building 580, babraham research campus, cambridge, cambridgeshire, CB22 3AT
Bank
-
Legal Advisor
-
new path molecular research ltd Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to new path molecular research ltd.
new path molecular research ltd Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for NEW PATH MOLECULAR RESEARCH LTD. This can take several minutes, an email will notify you when this has completed.
new path molecular research ltdCompanies House Filings - See Documents
